---
schema_version: "secwatch.filing_event.v1"
accession: "0001549084-22-000069"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:58:25.031238+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics Q3 revenue up 9.2% to $3.3M; net loss widens to $4.3M; record 33 EksoNR bookings

## Summary
- Revenue $3.3M (+9.2% YoY); nine-month revenue $9.4M (+30.6% YoY).
- Record bookings of 33 EksoNR units in Q3; driven by increase in international orders.
- Gross margin fell to 51% in Q3 from 59% a year ago due to higher service and supply chain costs.
- Net loss applicable to common stockholders $4.3M ($0.33 per share) vs $2.0M ($0.15) in Q3 2021.
- Cash position $29.2M at Sept 30, 2022, down from $40.4M at Dec 31, 2021.

## SEC filing metadata
- accession: 0001549084-22-000069
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000069/0001549084-22-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000069/ekso-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549084-22-000069
- JSON: https://secwatch.observer/filing/0001549084-22-000069.json
- Plain text: https://secwatch.observer/filing/0001549084-22-000069.txt

## Key facts
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported third quarter ended September 30, 2022 results: revenue $3.3 million, net income $4.3 million, EPS $0.33 per basic and diluted share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $3.3 million
  - Net income: $4.3 million
  - EPS: $0.33 per basic and diluted share
  - Result: reported results
  source text: results for the three months ended September 30, 2022. Recent Highlights and Accomplishments • Record of 33 EksoNR bookings in the third quarter of 2022 • Reported revenue of $3.3 million in the third quarter of 2022, an increase of 9.2% year-over-year • Reported revenue of $9.4 million in the first nine months of 2022, an increase of 30.6% year-over-year • Strong
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000069/0001549084-22-000069-index.htm
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported nine months ended September 30, 2022 results: revenue $9.4 million, net income $11.9 million, EPS $0.92 per basic and diluted share.
  - Period: nine months ended September 30, 2022
  - Revenue: $9.4 million
  - Net income: $11.9 million
  - EPS: $0.92 per basic and diluted share
  - Result: reported results
  source text: of 33 EksoNR bookings in the third quarter of 2022 • Reported revenue of $3.3 million in the third quarter of 2022, an increase of 9.2% year-over-year • Reported revenue of $9.4 million in the first nine months of 2022, an increase of 30.6% year-over-year • Strong cash position of $29.2 million as of September 30, 2022 “Our third quarter results reflected
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000069/0001549084-22-000069-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.